What does it take to turn a healthy snack from a confusing substitute for chocolate into a category people seek out? In this episode of The War Room, an entrepreneur follows that question from a childhood near Nagpur, shaped by farming and limited infrastructure, through an improbable detour into computer science and software products.

Returning to consumer business with Stevia, he saw a chance to link a natural sweetener to better farmer incomes. An approval roadblock stopped that plan. The next attempt, RightBite, exposed a different problem: a low-priced calcium bar could not persuade children expecting chocolate or retailers wary of an unfamiliar product.

He explains how listening harder to consumers shifted the company toward explicit functional benefits, then to a 20-gram Max Protein bar and a broader view of healthy snacking built around protein, fibre, fullness and sustained energy. He also shares why, after building the business to ₹160–170 crore, the completed Zydus Wellness partnership became the route to a far larger category-building ambition.

Cancer rarely stands still. Tumours evolve, treatments lose force, and recurrence can emerge long after an apparently reassuring scan. In this episode of The War Room, Mohan Utawar, co-founder and CEO of OneCell.ai, examines whether a more adaptive view of cancer can begin with a blood draw.

Utawar traces the path from invasive tissue biopsy to liquid biopsy, then makes the case for “cell biopsy”: isolating the exceptionally rare circulating tumour cells that may seed metastasis. He explains why finding those cells is only the first challenge. The larger task, he argues, is turning their morphology, surface markers, DNA, RNA, and protein signals into information that clinicians and trial teams can act on.

The conversation explores OneCell.ai’s OncoInsight assay, its combined ctDNA and live single-cell analysis, and the role AI could play in interpreting complex multiomics data. Utawar also discusses a biopharma-first route through clinical studies, companion diagnostics, validation, and reimbursement. At stake is a longer-term ambition: more affordable, minimally invasive monitoring that could help cancer care respond to change sooner.

One circulating tumour cell can be hidden among roughly a billion cells in blood. In this episode of The War Room, Mohan Utawar examines why finding that cell—and understanding what it means—could reshape precision cancer monitoring.

He traces the path from tissue biopsy and cell-free tumour DNA to “cell biopsy,” an approach centred on capturing live circulating tumour cells. The conversation explores how imaging, sequencing and multiomic analysis might combine DNA, RNA, proteins and cell features into a more useful picture of a cancer that continues to evolve.

The central question is not simply whether a signal can be detected. It is whether clinicians and trial teams can use it to judge therapy response, reconsider treatment and make better enrolment decisions before conventional imaging catches up. Mohan explains how OneCell.ai’s OncoInsight assay is intended to unite ctDNA and single-cell CTC analysis, and discusses the validation, regulatory, reimbursement and laboratory partnerships required to bring such tools into practice.

The episode closes on a larger ambition: earlier, minimally invasive and more affordable monitoring for people living beyond cancer treatment.

What can a blood draw reveal that a tissue biopsy cannot? In this episode of The War Room, the guest examines a proposed shift in precision oncology: from invasive tissue sampling and cell-free DNA to a “cell biopsy” built around intact circulating tumour cells. He explains why ctDNA remains useful but incomplete, and why rare tumour cells—described as fugitives on the run—may offer a more revealing starting point for cancer monitoring. The conversation traces OneCell.ai’s case for capturing live single cells, reading them alongside ctDNA, and combining DNA, RNA, targeted proteins, imaging and other molecular signals with AI. The question is not simply whether a signal can be found, but whether it can help clinicians judge treatment response, resistance and a cancer’s evolution over time. It also considers the realities of translation: laboratory deployment, biopharma studies, companion-diagnostic pathways, validation and reimbursement. The episode closes on the guest’s ambition to detect recurrence earlier through a simple blood draw and make actionable, affordable precision oncology more widely available to cancer survivors worldwide.

How much can a blood draw reveal about a cancer that is changing in real time? Mohan Utawar makes the case for looking beyond fragments of tumour DNA and toward the rare circulating tumour cells that may help drive recurrence and metastasis.

He traces the path from invasive tissue biopsy to liquid biopsy, explaining why ctDNA can offer a useful but partial signal. The conversation then examines OneCell.ai’s proposed “cell biopsy” approach: capturing live tumour cells from blood and analysing their DNA, RNA, proteins, morphology and other features with AI-assisted interpretation.

Utawar describes OncoInsight’s combined ctDNA and single-cell workflow, and addresses the harder question behind any result: what should clinicians and trial teams do next? He discusses longitudinal monitoring, molecular patient selection, treatment resistance, evidence-informed reporting, and the oncologist’s continuing responsibility for treatment decisions.

The episode also considers validation, regulatory and reimbursement paths, and a cautious longer-term ambition: detecting change and possible recurrence earlier, with a minimally invasive test that could make precision oncology more adaptive and accessible.

Recurrence and metastasis remain among cancer care’s hardest unresolved problems. In this episode, Mohan examines whether a blood draw can yield a more actionable view of a changing tumour.

He contrasts tissue biopsy and liquid biopsy before turning to circulating tumour cells: rare cells shed from solid tumours that may carry information DNA fragments alone cannot provide. OneCell’s proposed “cell biopsy” seeks to capture those cells—roughly one among a billion—then combine imaging, DNA, RNA, proteins and AI analysis.

Mohan explains why the aim is not simply to count cells, but to help oncologists interpret treatment response, resistance and cancer’s evolution over time. The conversation follows the practical path as well: OncoInsight’s integrated ctDNA and single-cell workflow, use in biopharma studies and companion diagnostics, and the evidence, regulatory and reimbursement work still ahead.

At stake is an ambitious proposition: earlier, less invasive monitoring for cancer survivors and a more affordable route to precision oncology.

A founder whose education began in a village barn turned repeated product setbacks into a protein-led healthy-snacking p

What does a responsible exit look like when a brand’s value was built by more than its founders? In this episode of The War Room, the founder of Natural and RightBite Max Protein traces the decision to sell a profitable healthy-snacking business to Zydus Wellness—and the test he used to judge the deal.

He explains how a simple customer insight changed the company’s ambition: gym-goers were eating protein bars as snacks, opening a wider market than post-workout nutrition. That shift made outside capital from Rabo India Agri Fund worth taking, alongside an ESOP intended to share eventual upside across the organisation.

Years later, growth from roughly ₹30 crore to ₹150 crore brought a new question: pursue another demanding scale-up or make room for a different chapter after 60. The conversation follows the difficult buyer search, the brand equity and distribution that made the business attractive, and a four-stakeholder framework spanning the brand, employees, shareholders and partners.

At the centre is an additional ₹5 crore employee pool reaching more than 250 people, with payouts extending beyond payroll. It is a story of product taste, profitable growth and what it takes to sell without leaving people behind.

How does a founder turn a blocked sweetener business and a nutrition bar nobody wants into a healthy-snacking platform? In this episode of The War Room, he traces the path from a childhood in a village near Nagpur—without a school, post office, or electricity—to agriculture, Silicon Valley product work, and a return to India.

He explains why Naturals began with Stevia, what happened when regulation halted that plan, and why RightBite’s early “healthy chocolate” pitch failed at both ₹15 and ₹5. Rather than retreat, he listens for a clearer consumer job: a snack with a functional purpose.

That shift reshapes the business. Distinct benefits for gym-goers, calorie-conscious consumers, and women’s nutrition lead to repeat purchase; a lesson about bars eaten alongside protein shakes helps define Max Protein. He then unpacks the move from protein bars to chips, cookies, granola, peanut butter, and plant protein—designed around protein, fibre, satiety, and sustained energy.

Finally, he reflects on the completed Zydus Wellness transaction and why category-building ambition now needs partners, resources, and expertise to grow.

How does a founder turn a product that will not move into a category consumers can finally see? In this episode, he traces a path from a village near Nagpur—where his early education began without basic infrastructure—to agriculture, computer science, Silicon Valley, and back to India to build products.

His first health-food mission was rooted in farmer income: Stevia promised a new crop and a consumer sweetener, until an approval roadblock intervened. The next attempt, RightBite nutrition bars priced for mass retail, exposed another hard truth. In Kirana stores, shoppers saw chocolate, not a health proposition.

He explains the shift that changed the business: put the functional benefit on the pack, identify a specific need, and follow actual consumer behaviour. That discipline led from workout bars to Max Protein, and from a single product to a broader healthy-snack platform spanning protein-and-fibre foods.

The conversation closes on growth, partnership, and the larger ambition behind the next chapter: creating healthier snack occasions at scale.